What happens if a company starts bioterror product development, invests millions of dollars, and fails?
That’s an outcome that companies are used to. Most of the larger companies have a diverse portfolio of products, and some of them are going to succeed and some of them aren’t. There’s no sure thing in biomedical development. Some good ideas just don’t pan out. And that’s OK. That’s the way we’re used to doing business.
